Abbott Laboratories (ABT) vs Novartis (NVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Novartis (NVS) has outperformed Abbott Laboratories (ABT) over the past year, gaining 18.2% versus a loss of 19.6%. Over five years, NVS leads with a +86.5% price change compared with -18.2% for ABT. Novartis is the larger company by market cap ($284.18 billion vs $178.39 billion), about 1.6 times the size.
On valuation, Novartis trades at a lower forward P/E (15.1x vs 17.3x for Abbott Laboratories). Novartis offers the higher dividend yield (3.10% vs 2.45%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABT | NVS |
|---|---|---|
| Share price | $103.00 | $150.47 |
| Market cap | $178.39B | $284.18B |
| 1-day change | -0.84% | -0.50% |
| YTD return | -17.79% | +9.14% |
| 1-year return | -19.60% | +18.19% |
| 5-year return | -18.18% | +86.46% |
| P/E ratio (TTM) | 38.43 | 28.72 |
| Forward P/E | 17.35 | 15.15 |
| EPS (TTM) | $2.68 | $5.24 |
| Dividend yield | 2.45% | 3.10% |
| Annual dividend | $2.52 | $4.67 |
| Revenue (latest FY) | $44.33B | — |
| Revenue growth (YoY) | +5.67% | — |
| Net income (latest FY) | $6.52B | $13.98B |
| Gross margin | 56.42% | — |
| Operating margin | 18.17% | — |
| Net margin | 14.72% | — |
| 52-week high | $129.85 | $170.46 |
| 52-week low | $81.97 | $126.50 |
| Distance from 52-week high | -20.68% | -11.73% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +15.45% | +4.41% |
| Average volume | 8.89M | 2.18M |
| Shares outstanding | 1.73B | 1.89B |
| Employees | 122,000 | 75,267 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVS has outperformed ABT by 37.8 percentage points over the past year.
- Abbott Laboratories trades at a higher earnings multiple (38.4x vs 28.7x trailing P/E).
About Abbott Laboratories
ABT stock →Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Health Care · Biotechnology: Pharmaceutical Preparations · 122,000 employees
About Novartis
NVS stock →Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees
ABT vs NVS FAQ
Which is bigger, Abbott Laboratories or Novartis?
Novartis (NVS) is larger, with a market capitalization of $284.18B compared with $178.39B for Abbott Laboratories (ABT).
Which stock has performed better over the past year, ABT or NVS?
NVS returned +18.19% over the past 12 months, compared with -19.60% for ABT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABT or NVS?
NVS has the lower trailing P/E at 28.7, versus 38.4 for ABT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Abbott Laboratories or Novartis?
Novartis has the higher yield at 3.10%, compared with 2.45% for Abbott Laboratories.
Are Abbott Laboratories and Novartis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.